Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04130438 · ClinicalTrials.gov registry record · Phase 2

Efficacy of Medical Therapy in Women and Men With Angina and Myocardial Bridging

A Phase 2 study, sponsored by Stanford University.

Terminated
Registry status
Phase 2
Development phase
5
Enrollment target

NCT04130438: Clinical Trial Phase 2 study, sponsored by Stanford University.

NCT04130438 is a Phase 2 study that was terminated before completion, run by Stanford University. The registered enrollment target is 5 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04130438, a Phase 2 study, was terminated before completion, sponsored by Stanford University.

TERMINATED
Registry status
Phase 2
Development phase
5 participants
Enrollment target

Study Summary

The proposed clinical trial is relevant to public health because it is expected to expand the differential diagnosis and provide an evidence--based therapy for the large population of patients with angina in the absence of obstructive CAD who currently remain undiagnosed and untreated. It, therefore, upholds an important part of the mission of the The National Heart, Lung, and Blood Institute (NHLBI), which is to promote the treatment of heart disease and enhance the health of all individuals so that they can live longer and more fulfilling lives.

Interventions

  • OTHER Placebo
  • DRUG Nebivolol
  • DRUG Diltiazem

Trial Details

FieldValue
Enrollment Target 5 participants
Start Date 2020-10-15
Est. Completion 2024-10-17
Phase Phase 2

Sponsor

Stanford University

1,744 total trials

What the Registry Record Tells You About NCT04130438

The ClinicalTrials.gov registry entry for NCT04130438 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.

NCT04130438 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04130438 about?

NCT04130438 is a clinical study titled "Efficacy of Medical Therapy in Women and Men With Angina and Myocardial Bridging". The proposed clinical trial is relevant to public health because it is expected to expand the differential diagnosis and provide an evidence--based therapy for the large population of patients with angina in the absence of obstructive CAD who currently remain undiagnosed and untreated. It, therefore...

What is the current status of trial NCT04130438?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2020-10-15. Estimated completion is 2024-10-17.

What interventions are being tested in trial NCT04130438?

The interventions under investigation include: Placebo (OTHER), Nebivolol (DRUG), Diltiazem (DRUG).

Who is sponsoring clinical trial NCT04130438?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.